All Type of News
MOHW enforces ‘introduction of pharmaceutical dispensers’, opposed by KPA
Since the introduction of pharmaceutical dispensers started the countdown, the pharmaceutical industry has strongly opposed to it.
On the 27th, the Ministry of Health and Welfare(MOHW) gave a notice on the Partial Am...
Rebates judge pharmaceutical companies’ destiny
The rebate investigation on pharmaceutical companies has been strongly conducted, enough to share their destiny.
While the pharmaceutical industry has internally said the prosecution-inspected company P will get dama...
Distribution association works on Pharmaceutical Affairs Law to block hospitals over direct distribution
The pharmaceutical distribution association will get started on moves to stop medical institutes to exercise practical influences on pharmaceutical distribution companies through participation of shares.
The Korea P...
Brexit alerts pharmaceutical industry, too
It seems the Brexit crisis will bring huge impacts on the domestic pharmaceutical industry, too. It rarely influences on the real economy, such as the domestic pharmaceutical economy and pharmaceutical exports, but is...
Domestic pharmaceutical companies focus on development of salt-modified drugs and generics of ‘Viread’The hepatitis B therapy which recorded KRW 125.3 billion prescriptions in Korea last year, Viread(generic name: tenofovir, Gilead), will be expired in patent. Thus, pharmaceutic...
|
AstraZeneca confirms Early Retirement Program, paying No. of year * 2 + 8-month wageAstraZeneca Korea has actively started to reduce the number of employees.
The company confirmed to run the Early Retirement Program(ERP) recently, informed it internally.
The ...
|
Creation of ‘olmesartan’ administration prohibition on chronic malabsorption patients
The antihypertensive olmesartan’s safety issue has been settled by newly creating a measure about prohibition of administration on chronic malabsorption syndrome patients in the approval article of olmesartan.
On the...
Hanmi strengthens sales & marketing in ophthalmologic fieldHanmi Pharm will drastically strengthen sales, marketing and R&D on the ophthalmologic field.
On the 23rd, Hanmi Pharm(CEO Kwan-soon Lee) announced reorganization of the ophth...
|
Next-generation dementia therapy’s Phase 3 clinical trials starts in Korea
The next generation dementia therapy, which was expected to generate approximately KRW 1 trillion prescriptions in the global market, was approved to conduct Phase 3 clinical trials in Korea.
The therapy is ‘RVT-101’...
Domestic companies challenge inhaler market being monopolized by foreign ones
A series of domestic pharmaceutical companies have given prior notices to enter the inhaler market whose product dependency is mostly high on multinational companies.
Inhalers are usually launched by a small number o...
